Marketing attribution vs the traditional approach: what actually beats what for healthcare and life sciences in the Middle East

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the Middle East. In this market, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing, so the way you install marketing attribution has to be shaped to that reality from day one.

The debate about marketing attribution is often framed as replacement — new model wipes out old. That framing is wrong. The right question is where each approach wins.

Marketing attribution wins on speed of learning, targeting precision, and cost per outcome. It is the honest answer to which activities create pipeline, and it compounds in ways the traditional approach cannot match.

The traditional approach wins on relationship depth, brand consistency, and situations where the buyer has already self-identified. Ignoring that is why some teams' first marketing attribution attempt underperforms — they replace the wrong parts.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the Middle East it is compounded by the fact that senior-relationship access, not product is what actually gates growth. Marketing attribution is only useful here when it is pointed at both constraints at once.

Combine them deliberately. Use marketing attribution to find and qualify; use the traditional approach to close and expand. The seam between them is where most pipeline is lost or won.

Metric to watch when running both: attribution model reconciled to closed-won, plus source attribution. The two approaches should not cannibalise each other; if they do, your handoff is broken.

The failure mode of running both is picking a model to defend a budget instead of to learn — usually because the traditional team feels threatened and the new model is starved of context.

Companies that get this right end up with a hybrid engine that outperforms either pure model. Companies that pick one and evangelise it lose to the ones that combine.

Concretely for healthcare and life sciences in the Middle East: the healthcare teams that install this get past procurement instead of dying in it, and one sovereign or family-office win in the Middle East justifies a full year of program spend. That is the reason it is worth installing marketing attribution deliberately for this market rather than importing a playbook designed for somewhere else.